BioCryst Pharmaceuticals Ownership | Who Owns BioCryst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

BioCryst Pharmaceuticals Ownership Summary


BioCryst Pharmaceuticals is owned by 81.02% institutional investors, 1.46% insiders, and 17.52% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.68% of BCRX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.14% of its assets in BioCryst Pharmaceuticals shares.

BCRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBioCryst Pharmaceuticals81.02%1.46%17.52%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de22.10M10.68%$166.16M
Vanguard group21.89M10.58%$164.62M
Blackrock19.96M9.68%$123.33M
Avoro capital advisors11.87M5.73%$89.22M
Kynam capital management, lp9.09M4.39%$68.32M
Deerfield management company, l.p. (series c)8.14M3.94%$61.25M
State street7.50M3.62%$56.39M
Alkeon capital management7.09M3.43%$53.35M
Geode capital management4.82M2.33%$36.28M
Rp management3.85M1.86%$29.23M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rp management3.85M12.84%$29.23M
Caligan partners lp3.00M5.71%$22.53M
Kynam capital management, lp9.09M4.04%$68.32M
Oracle investment management535.56K2.19%$4.03M
Eversept partners, lp1.98M1.32%$14.89M
Dafna capital management667.00K1.27%$5.02M
Avoro capital advisors11.87M1.26%$89.22M
Knott david m jr440.00K1.20%$3.31M
Deerfield management company, l.p. (series c)8.14M1.16%$61.25M
Rice hall james & associates2.08M0.86%$15.65M

Top Buyers

HolderShares% AssetsChange
Vanguard group21.89M0.00%1.58M
Blackrock19.96M0.00%1.52M
Eversept partners, lp1.98M1.32%1.44M
Blackrock funding, inc. /de22.10M0.00%1.18M
Cubist systematic strategies1.11M0.05%935.13K

Top Sellers

HolderShares% AssetsChange
Braidwell lp---3.38M
Price t rowe associates inc /md/126.81K0.00%-2.13M
Point72 asset management---1.62M
Nuveen asset management3.42M0.01%-1.40M
State street7.50M0.00%-1.35M

New Positions

HolderShares% AssetsChangeValue
Balyasny asset management529.65K0.01%529.65K$3.98M
Norges bank524.80K0.00%524.80K$3.95M
Woodline partners lp450.20K0.02%450.20K$3.39M
Graham capital management97.26K0.01%97.26K$731.37K
Susquehanna fundamental investments88.85K0.01%88.85K$668.18K

Sold Out

HolderChange
Tfo-tdc-3.00
Financial gravity asset management-8.00
Dinuzzo private wealth-13.00
Newbridge financial services group-15.00
Sjs investment consulting-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024265-1.49%167,630,080-2.81%811.17%114-14.29%8717.57%
Sep 30, 20242687.63%172,429,027-1.07%831.17%1345.51%738.96%
Jun 30, 2024246-1.99%174,231,087-2.64%841.12%1257.76%67-4.29%
Mar 31, 20242511.62%178,960,7401.28%861.03%1163.57%70-10.26%
Dec 31, 20232471.65%176,694,3881.14%911.08%112-7.44%7834.48%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF6.57M3.14%-18.55K
Vanguard Total Stock Mkt Idx Inv6.52M3.12%5.94K
iShares Russell 2000 ETF5.43M2.60%-47.02K
Vanguard Institutional Extnd Mkt Idx Tr3.13M1.50%28.24K
SPDR® S&P Biotech ETF3.10M1.49%-33.26K
Vanguard Small Cap Index2.64M1.27%2.19K
Fidelity Small Cap Index2.03M0.97%-38.08K
Vanguard Strategic Equity Inv1.83M0.89%317.26K
iShares Russell 2000 Growth ETF1.83M0.88%-8.71K
Vanguard Explorer Inv1.79M0.87%426.10K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 13, 2024Hutson Nancy J-Sell$52.78K
Jun 24, 2024McKee Amy E-Sell$54.35K
Jun 17, 2024SANDERS MACHELLE-Sell$28.13K
Jun 14, 2024HEGGIE THERESA-Sell$40.92K
May 30, 2024LEVIN ALAN G-Buy$50.00K

Insider Transactions Trends


DateBuySell
2025 Q1--
2024 Q4-1
2024 Q3--
2024 Q2103
2024 Q1--

BCRX Ownership FAQ


Who Owns BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals shareholders are primarily institutional investors at 81.02%, followed by 1.46% insiders and 17.52% retail investors. The average institutional ownership in BioCryst Pharmaceuticals's industry, Biotech Stocks , is 68.48%, which BioCryst Pharmaceuticals exceeds.

Who owns the most shares of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (22.1M shares, 10.68%), Vanguard group (21.89M shares, 10.58%), and Blackrock (19.96M shares, 9.68%). Together, they hold 30.94% of BioCryst Pharmaceuticals’s total shares outstanding.

Does Blackrock own BioCryst Pharmaceuticals?

Yes, BlackRock owns 9.68% of BioCryst Pharmaceuticals, totaling 19.96M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 123.33M$. In the last quarter, BlackRock increased its holdings by 1.52M shares, a 8.22% change.

Who is BioCryst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Rp management is BioCryst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 12.84% of its assets in 3.85M BioCryst Pharmaceuticals shares, valued at 29.23M$.

Who is the top mutual fund holder of BioCryst Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of BioCryst Pharmaceuticals shares, with 3.14% of its total shares outstanding invested in 6.57M BioCryst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools